Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PassPort Reports Positive Interim Phase 1 Results for Zolmitriptan
Details : Zolmitriptan PassPort (zolmitriptan) is a 5-HT1D/5-HT1B binder, small molecule drug, transdermal patch. It is being evaluated in phase 1 clinical trials for the treatment of acute migraine.
Product Name : Zolmitriptan PassPort
Product Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2024
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PassPort Technologies Initiates Phase 1 of Zolmitriptan Transdermal System for Migraines
Details : Zolmitriptan PassPort (zolmitriptan) is a 5-HT1D/5-HT1B binder, small molecule drug, transdermal patch. It is being evaluated in phase 1 clinical trials for the treatment of acute migraine.
Product Name : Zolmitriptan PassPort
Product Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2024
Lead Product(s) : Zolmitriptan
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable